Travere Therapeutics, Inc. (RTRX) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1159932,
    "name": "Travere Therapeutics, Inc.",
    "stock_name": "Travere Therapeutics, Inc.",
    "full_name": "Travere Therapeutics, Inc.",
    "name_url": "stocks-analysis/travere-therapeutics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "35.33",
    "chg": 1.34,
    "chgp": "3.94%",
    "dir": 1,
    "prev_price": "33.99",
    "mcapval": "1,889.74",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US89422G1076",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "2.87 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/travere-therapeutics-inc-1159932-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Travere Therapeutics Stock Hits Day High with 18.58% Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/travere-therapeutics-stock-hits-day-high-with-1858-surge-3667393",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/TravereTherapeu_priceRelatedfactors_3667393.png",
        "date": "2025-11-03 17:44:35",
        "description": "Travere Therapeutics, Inc. has seen notable stock activity, with significant gains over the past week and month, as well as impressive year-to-date returns. The company reported a substantial increase in net sales and achieved its highest operating cash flow recently, reflecting strong performance in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Travere Therapeutics Hits New 52-Week High of $35.34, Marking Major Growth",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/travere-therapeutics-hits-new-52-week-high-of-3534-marking-major-growth-3667329",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/TravereTherapeu_priceRelatedfactors_3667329.png",
        "date": "2025-11-03 17:14:06",
        "description": "Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 1,890 million, has reported a 40.03% rise in net sales and positive results for three consecutive quarters, despite operating losses."
      },
      {
        "title": "Travere Therapeutics Achieves 100.91% Return, Marking It as a Multibagger in Pharmaceuticals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/travere-therapeutics-achieves-10091-return-marking-it-as-a-multibagger-in-pharmaceuticals-3666986",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/TravereTherapeu_multibagger_3666986.png",
        "date": "2025-11-03 15:11:57",
        "description": "Travere Therapeutics, Inc. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved significant growth in net sales and has consistently reported positive results over the past quarters, further enhancing its appeal in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Travere Therapeutics Hits New 52-Week High of $28.85, Surging 286%",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/travere-therapeutics-hits-new-52-week-high-of-2885-surging-286-3649280",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/TravereTherapeu_priceRelatedfactors_3649280.png",
        "date": "2025-10-27 16:58:28",
        "description": "Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a 285.97% increase over the past year. The company reported a 40.03% growth in net sales, totaling USD 114.45 million, and has shown positive results for three consecutive quarters, indicating strong financial health."
      },
      {
        "title": "Travere Therapeutics, Inc. Reports Strong Financial Performance in Q2 2025",
        "link": "https://www.marketsmojo.com/news/mojo-premium/travere-therapeutics-enters-reliable-performers-strategy-amid-strong-financial-results-3565576",
        "imagepath": "",
        "date": "2025-09-24 14:53:42",
        "description": "<p><strong>Travere Therapeutics, Inc.</strong>, a small-cap company operating in the Pharmaceuticals & Biotechnology sector, has reported a very positive financial performance for the quarter ending June 2025. The results indicate significant growth and operational efficiency, showcasing the company's potential in the market.</p>\n\n<p>During this quarter, <strong>Travere Therapeutics</strong> achieved its highest operating cash flow at USD -115.44 MM, reflecting a robust financial position despite the negative figure. The company also recorded its highest net sales at USD 114.45 MM, indicating strong demand for its products.</p>\n\n<p>The operating profit margin reached a notable 1.19%, marking an improvement in profitability metrics. Additionally, the raw material costs saw a significant decrease of 12.28% year-over-year, which may contribute positively to the company's overall financial health.</p>\n\n<p>Furth..."
      },
      {
        "title": "Is Travere Therapeutics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-travere-therapeutics-inc-technically-bullish-or-bearish-3547328",
        "imagepath": "",
        "date": "2025-09-20 19:52:56",
        "description": "As of 5 August 2025, the technical trend for Travere Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and Bollinger Bands are both bullish, while the daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the Dow Theory shows no trend on the weekly but is mildly bullish on the monthly. The stock has performed well over the past month with a return of 28.88%, significantly outperforming the S&P 500's 2.33% return in the same period. Overall, the current technical stance is mildly bullish, driven by strong indicators in the MACD, Bollinger Bands, and moving averages...."
      },
      {
        "title": "Is Travere Therapeutics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-travere-therapeutics-inc-overvalued-or-undervalued-3543730",
        "imagepath": "",
        "date": "2025-09-20 18:27:08",
        "description": "As of 3 November 2016, the valuation grade for Travere Therapeutics, Inc. changed from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, as evidenced by a Price to Book Value of 41.45 and negative EV to EBIT and EV to EBITDA ratios of -6.32 and -7.97, respectively. Additionally, the company's ROCE and ROE are significantly negative at -235.78% and -681.59%, highlighting severe operational inefficiencies.\n\nIn comparison to peers, Travere's valuation ratios are concerning; for instance, Amneal Pharmaceuticals, Inc. has a P/E ratio of 48.88, while NewAmsterdam Pharma Co. NV shows a P/E of -20.32, both indicating a more favorable valuation landscape. Furthermore, despite a strong 1Y stock return of 68.57% compared to the S&P 500's 17.14%, the long-term performance over 3Y and 5Y shows negative returns for Travere, suggesting that its ..."
      },
      {
        "title": "Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/travere-therapeutics-forms-golden-cross-signaling-bullish-breakout-ahead-3537572",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/9/TravereTherapeu_goldencross_3537572.png",
        "date": "2025-09-19 16:04:43",
        "description": "Travere Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock displays a bullish outlook across various technical indicators, despite a short-term decline. Over the past year, it has significantly outperformed the S&P 500, suggesting growing investor interest in the biotechnology sector."
      }
    ],
    "total": 12,
    "sid": "1159932",
    "stock_news_url": "https://www.marketsmojo.com/news/travere-therapeutics-inc-1159932"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Travere Therapeutics Stock Hits Day High with 18.58% Surge

2025-11-03 17:44:35

Travere Therapeutics, Inc. has seen notable stock activity, with significant gains over the past week and month, as well as impressive year-to-date returns. The company reported a substantial increase in net sales and achieved its highest operating cash flow recently, reflecting strong performance in the Pharmaceuticals & Biotechnology sector.

Travere Therapeutics Hits New 52-Week High of $35.34, Marking Major Growth

2025-11-03 17:14:06

Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 1,890 million, has reported a 40.03% rise in net sales and positive results for three consecutive quarters, despite operating losses.

Travere Therapeutics Achieves 100.91% Return, Marking It as a Multibagger in Pharmaceuticals

2025-11-03 15:11:57

Travere Therapeutics, Inc. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved significant growth in net sales and has consistently reported positive results over the past quarters, further enhancing its appeal in the Pharmaceuticals & Biotechnology sector.

Travere Therapeutics Hits New 52-Week High of $28.85, Surging 286%

2025-10-27 16:58:28

Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a 285.97% increase over the past year. The company reported a 40.03% growth in net sales, totaling USD 114.45 million, and has shown positive results for three consecutive quarters, indicating strong financial health.

Travere Therapeutics, Inc. Reports Strong Financial Performance in Q2 2025

2025-09-24 14:53:42

Travere Therapeutics, Inc., a small-cap company operating in the Pharmaceuticals & Biotechnology sector, has reported a very positive financial performance for the quarter ending June 2025. The results indicate significant growth and operational efficiency, showcasing the company's potential in the market.

During this quarter, Travere Therapeutics achieved its highest operating cash flow at USD -115.44 MM, reflecting a robust financial position despite the negative figure. The company also recorded its highest net sales at USD 114.45 MM, indicating strong demand for its products.

The operating profit margin reached a notable 1.19%, marking an improvement in profitability metrics. Additionally, the raw material costs saw a significant decrease of 12.28% year-over-year, which may contribute positively to the company's overall financial health.

Furth...

Is Travere Therapeutics, Inc. technically bullish or bearish?

2025-09-20 19:52:56

As of 5 August 2025, the technical trend for Travere Therapeutics, Inc. has changed from sideways to mildly bullish. The weekly MACD and Bollinger Bands are both bullish, while the daily moving averages also indicate a bullish stance. However, the weekly RSI is bearish, and the Dow Theory shows no trend on the weekly but is mildly bullish on the monthly. The stock has performed well over the past month with a return of 28.88%, significantly outperforming the S&P 500's 2.33% return in the same period. Overall, the current technical stance is mildly bullish, driven by strong indicators in the MACD, Bollinger Bands, and moving averages....

Is Travere Therapeutics, Inc. overvalued or undervalued?

2025-09-20 18:27:08

As of 3 November 2016, the valuation grade for Travere Therapeutics, Inc. changed from attractive to risky, indicating a shift in perception regarding its investment potential. The company appears to be overvalued, as evidenced by a Price to Book Value of 41.45 and negative EV to EBIT and EV to EBITDA ratios of -6.32 and -7.97, respectively. Additionally, the company's ROCE and ROE are significantly negative at -235.78% and -681.59%, highlighting severe operational inefficiencies. In comparison to peers, Travere's valuation ratios are concerning; for instance, Amneal Pharmaceuticals, Inc. has a P/E ratio of 48.88, while NewAmsterdam Pharma Co. NV shows a P/E of -20.32, both indicating a more favorable valuation landscape. Furthermore, despite a strong 1Y stock return of 68.57% compared to the S&P 500's 17.14%, the long-term performance over 3Y and 5Y shows negative returns for Travere, suggesting that its ...

Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead

2025-09-19 16:04:43

Travere Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock displays a bullish outlook across various technical indicators, despite a short-term decline. Over the past year, it has significantly outperformed the S&P 500, suggesting growing investor interest in the biotechnology sector.

View All News